Full Circles Therapeutics Inc.

Full Circles Therapeutics Inc.

Biotechnology

Cambridge, MA 2,043 followers

Genome Engineering Comes Full Circle. Harnessing revolutionary, virus-free, technology for DNA reading and writing.

About us

Full Circles Therapeutics is transforming genome engineering with our unique, nonviral, targeted genomic integration technology to treat genetic diseases and cancer. Our GATALYST platform delivers circular, single-stranded DNA for integration into genomic safe harbors (GSH) in disease-relevant cell types, with no limitations on the size of the donor DNA sequence. With our targeted genome engineering approach, we are dedicated to discovering, developing, and manufacturing novel and curative genomic therapies. We aim to bridge the gap between technology and treatment – bringing gene editing full circle to forge a brighter future for patients and their families.

Website
https://fullcirclestx.com/
Industry
Biotechnology
Company size
11-50 employees
Headquarters
Cambridge, MA
Type
Privately Held

Locations

Employees at Full Circles Therapeutics Inc.

Updates

  • Full Circles Therapeutics Inc. reposted this

    View profile for Richard Shan, graphic

    Customer Support Scientist, Quintara Biosciences, Inc.

    Thank you, Mark! You are among the first group of people who used C4DNA. The Full Circles team is great under the leadership of Howard Wu, and much of the work after 2022 was done under extremely tight budgets and with generous support from Quintara Biosciences There are many unsung heroes behind the Full Circles story. The initial idea on single stranded DNA was from Jianxin Hu in the summer of 2016. Jianxin was working on human diseases model in Biogen, and needed ssDNA for his transgenic work. Much of the early knowledge on ssDNA as a better HDR donor template was from Jianxin. Jianxin was Quintara DNA sequencing customer during his postdoc in the Black lab at UCSF. Jin Huh did the initial set of experiments which gave us the first hint that circular form works better than the linear form. Jin was one of my very first DNA sequencing customer when the synbio just started in Potter Street, off Berkeley campus. Fortunately I met Jin again in Boston where he did his postdoc at the Weiss lab of MIT. Mark Neff, Ph.D. was the one helped me get the thoughts organized, and drafted the foundation IP. Mark flew to the Bay Area, and spent an entire month helping me draft the IP application and talked with IP lawyers at Perkins. Mark and I did postdoc together in Berkeley. Mark is the best dog geneticist and a true life long friend. Tae-Gon Cha did his postdoc in the Voigt lab at MIT. The Voigt lab was my first generation DNA sequencing customer, started at the Berkeley, later at UCSF, and recently at MIT. Quintara followed Chris’s footsteps and set up our Boston lab. Without Quintara’s Boston lab, there is no Full Circles. I visited the Voigt lab around Thanksgiving time in 2017, and got a chance to talk with TG who just joined the Voigt lab from Purdue. TG was trained as a material scientist and worked on biological battery based on phage M13. I was attracted by the elegant engineered phagemid system TG developed. Our C4 DNA system was largely inspired by TG phagemid systems. I am very grateful that TG later worked for Full Circles for one year. Michael Cox is my graduate advisor at UW-Madison. Mike is the best advisor I can ever dream of. He is never on my way but his support is always there when I needed. I studied the mechanism of homologous DNA recombination using RecA mediated DNA strand exchange as a model system. Mike developed the system when he did his postdoc with Bob Lehman at Stanford. We use circular single stranded DNA (M13 virion DNA) in the DNA strand exchange reaction. Mike sent all the phage materials from Madison . Full Circles Therapeutics Inc. comes from my life long journey on cssDNA. Mike and I found RecA could form stable nucleoprotein filaments on cssDNA but not on lssDNA. I started to realize cssDNA potential in current paper. I told Mike cssDNA comes in a Full Circle. Many people helped, especially those helped financially.

    We are beyond thrilled to announce our recent publication in Nature Biotechnology and the grant of a pivotal patent for our innovative non-viral gene editing approach. The paper titled “Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration" can be accessed at https://lnkd.in/gH3pcfRn In this study, we introduce a revolutionary technology that addresses the key challenges of conventional immune cell modification methods, such as viral vector-based gene editing. Our approach uses a miniaturized circular single-stranded DNA (cssDNA), an unparalleled form of its kind, to enable stable, safe, efficient and precise genomic integration in immune cells without the risks of viral delivery systems. This breakthrough has the potential to transform gene therapies, providing safer, more efficient, and cost effective solutions for a variety of diseases, including cancer and autoimmune disorders. "We believe this non-viral method of immune cell engineering marks a transformative advancement in the field," said Dr. Howard (Hao) Wu, Chief Scientific Officer of Full Circles Therapeutics. "By leveraging our proprietary C4DNAtechnology, we can enhance the safety, scalability, and efficiency of engineered immune cells such as CAR-T and CAR-NK, pushing us closer to the development of off-the-shelf, ready-to-use therapies." We're also excited to share that the foundational patent for this technology has been granted in Japan—one of the leading global markets in oncology and gene therapy. The patent covers the use of generic circular ssDNA for targeted genome integration, with promising preclinical results. "We're excited about the broad potential of this technology," said Dr. Richard Shan, CEO of Full Circles Therapeutics. "This breakthrough can revolutionize treatments for diseases traditionally difficult to tackle with conventional methods. Our mission is to make these therapies more accessible, scalable, and effective, advancing patient care across the globe." Big shoutouts to all our collaborators and team members for making this groundbreaking work possible! #ImmuneCellEngineering #GeneTherapy #NonViralTech #CAR-T #Immunotherapy #FullCirclesTherapeutics #NatureBiotechnology #C4DNA #CellAndGeneTherapy

    Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration - Nature Biotechnology

    Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration - Nature Biotechnology

    nature.com

  • We are beyond thrilled to announce our recent publication in Nature Biotechnology and the grant of a pivotal patent for our innovative non-viral gene editing approach. The paper titled “Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration" can be accessed at https://lnkd.in/gH3pcfRn In this study, we introduce a revolutionary technology that addresses the key challenges of conventional immune cell modification methods, such as viral vector-based gene editing. Our approach uses a miniaturized circular single-stranded DNA (cssDNA), an unparalleled form of its kind, to enable stable, safe, efficient and precise genomic integration in immune cells without the risks of viral delivery systems. This breakthrough has the potential to transform gene therapies, providing safer, more efficient, and cost effective solutions for a variety of diseases, including cancer and autoimmune disorders. "We believe this non-viral method of immune cell engineering marks a transformative advancement in the field," said Dr. Howard (Hao) Wu, Chief Scientific Officer of Full Circles Therapeutics. "By leveraging our proprietary C4DNAtechnology, we can enhance the safety, scalability, and efficiency of engineered immune cells such as CAR-T and CAR-NK, pushing us closer to the development of off-the-shelf, ready-to-use therapies." We're also excited to share that the foundational patent for this technology has been granted in Japan—one of the leading global markets in oncology and gene therapy. The patent covers the use of generic circular ssDNA for targeted genome integration, with promising preclinical results. "We're excited about the broad potential of this technology," said Dr. Richard Shan, CEO of Full Circles Therapeutics. "This breakthrough can revolutionize treatments for diseases traditionally difficult to tackle with conventional methods. Our mission is to make these therapies more accessible, scalable, and effective, advancing patient care across the globe." Big shoutouts to all our collaborators and team members for making this groundbreaking work possible! #ImmuneCellEngineering #GeneTherapy #NonViralTech #CAR-T #Immunotherapy #FullCirclesTherapeutics #NatureBiotechnology #C4DNA #CellAndGeneTherapy

    Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration - Nature Biotechnology

    Efficient non-viral immune cell engineering using circular single-stranded DNA-mediated genomic integration - Nature Biotechnology

    nature.com

  • Full Circles Therapeutics Inc. reposted this

    𝐄𝐟𝐟𝐢𝐜𝐢𝐞𝐧𝐭 𝐧𝐨𝐧-𝐯𝐢𝐫𝐚𝐥 𝐢𝐦𝐦𝐮𝐧𝐞 𝐜𝐞𝐥𝐥 𝐞𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐮𝐬𝐢𝐧𝐠 𝐜𝐢𝐫𝐜𝐮𝐥𝐚𝐫 𝐬𝐢𝐧𝐠𝐥𝐞-𝐬𝐭𝐫𝐚𝐧𝐝𝐞𝐝 𝐃𝐍𝐀-𝐦𝐞𝐝𝐢𝐚𝐭𝐞𝐝 𝐠𝐞𝐧𝐨𝐦𝐢𝐜 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 Scientists at Full Circles Therapeutics Inc. have developed a novel circular single-stranded DNA technology that enables highly efficient gene integration in various cell types, achieving up to 70% successful gene integration. The system can carry genetic sequences of up to 20 kb in length, showing promise for CAR-T cell therapy development. Their work was published in Nature Biotechnology this morning. Read more in our interview with co-founder and CSO Hao Wu. Interview by Christos Evangelou, PhD, BCMAS #crisprmedicinenews #crisprmedicine #breakingnews #cancertherapy #nonviralgenetherapy #geneediting #crispr https://lnkd.in/eesin8iq

    • No alternative text description for this image
  • Cambridge, MA USA – Oct 20, 2024 – Full Circles Therapeutics, a leading innovator in the targeted therapies space, is pleased to announce the successful grant of one of its foundational patents by the Japan Patent Office. This milestone marks a significant step forward in the company’s mission to enhance treatment options for patients suffering from autoimmune diseases, genetic metabolic disorders and oncology with non-viral genetic therapy. The newly granted patent covers the use of generic circular single stranded DNA forms for targeted genome integration, which has shown promising results in preclinical studies. This technology aims to enable next generation of safe and efficient genome writing in a targeted, nuclease editor agnostic, highly adaptable non-viral cell and gene therapy. “We are excited about the grant of this patent in Japan, which recognizes our commitment to innovation and patient-centered solutions,” said Howard Wu, CSO of Full Circles Therapeutics. “This development not only strengthens our intellectual property portfolio but also positions us strategically in one of the major pharmaceutical markets in the world.” The patent, along with others in filing, is part of Full Circles Therapeutics’ broader strategy to advance its research and development efforts, with ongoing pre-clinical studies via external collaborations aimed at bringing new non-viral genetic medicine to market. The company remains dedicated to collaborating with partners in the healthcare sector to accelerate the availability of breakthrough treatments. Full Circles Therapeutics continues to seek opportunities for international expansion and innovation, and external partnership, ensuring that its cutting-edge solutions are accessible to patients globally. For more information about Full Circles Therapeutics and licensing partner opportunities, please visit www.fullcirclestx.com or contact admin@fullcirclestx.com.

    • No alternative text description for this image
  • Full Circles Therapeutics Inc. reposted this

    Columbia University launches groundbreaking initiative in cell engineering and therapy, led by CAR T-cell pioneer and ASGCT past-president, Michel Sadelain, MD, PhD. Key points: - Dr. Sadelain, past president and current member of ASGCT, appointed to head the Columbia Initiative in Cell Engineering and Therapy (CICET) - Focus on advancing cell and gene therapies for cancer, autoimmune diseases, and genetic disorders - Initiative to create synergies with existing Columbia research programs Aims to attract leading scientists and enhance research infrastructure - Dr. Sadelain to also direct Cancer Cell Therapy Initiative at Columbia's Herbert Irving Comprehensive Cancer Center Read the entire article, written by Aleka Gomez-Sotomayor-Roel, here: https://lnkd.in/eY465jSQ This initiative marks a significant step in expanding #celltherapy applications, potentially transforming treatments for a wide range of diseases. #cgt #ASGCT #cellandgenetherapy

    Michel Sadelain to head Columbia’s cell therapy and engineering initiative

    Michel Sadelain to head Columbia’s cell therapy and engineering initiative

    columbiaspectator.com

  • At the heart of Full Circles Therapeutics Inc. ‘s innovation is our viral-free genome engineering platform, a proprietary technol- ogy that utilizes a scalable and programmable C4DNA. This unique DNA molecule enables the integration of extra- large genetic payloads into the genome in locus specific manner, a feat previously not easy to achieve. C4DNA presents several advantages, including that it is non-viral, can be scalably manufactured to the milligram to gram level, and has a shorter half-life than conventional double-stranded (ds) DNA, hence lower cytotoxicity to the cells and less concerns for random integration. C4DNA also enables highly efficient targeted genome integration, with a molecular weight of only half of dsDNA counterparts, leading to easy delivery of high copy numbers. Moreover, C4DNA’s programmability allows for the incorporation of polycistronic cassettes, enabling genetic circuit engineering. C4DNA can be used with payloads of up to 25 kb, and at Full Circles so far, developers are achieving 10–15 kb docking with satisfactory knock-in efficiency. The goal is to correct multiple mutations through the insertion of extra-large payloads. This platform will be useful in working to address diseases or genetic disorders with extra-large genetic root cause genes in a mutation agnostic manner, such as cystic fibrosis, Stargardt syndrome, and otoferlin-related hearing loss, as well as in immuno-oncology applications.

    View profile for Hao Wu, graphic

    Co-Founder and CSO at Gene Editing Biotech, inventor for Epigenetic editing

    I’m excited to share that my recent interview has been published in Cell & Gene Therapy Insights! In this article, I delved into the latest advancements in genome and epigenome editing and their pivotal role in shaping the future of cell and gene therapies. I also highlighted Full Circles Therapeutics Inc. #C4DNA non-viral platform as a non-viral delivery approach for targeted ultralarge transgene integration as well as other emerging genome and epigenome editing technologies. These groundbreaking innovations hold the potential to revolutionize treatment approaches and could potentially significantly enhance patient outcomes. I also addressed the challenges in the translational path for genome and epigenome editing and explore potential strategies to overcome these obstacles in advanced therapies. Please find the article here https://lnkd.in/ezGSrruG A big thank you to the team at Cell & Gene Therapy Insights for the opportunity to contribute to this important conversation! #CGT #geneediting #DNAwriting #C4DNA #epigenomeediting #nonviral

    Pioneering the future of non-viral genome engineering

    Pioneering the future of non-viral genome engineering

    insights.bio

  • Full Circles Therapeutics Inc. reposted this

    We are thrilled to welcome two incredible new companies to our innovative Portal Southline ecosystem, Full Circles Therapeutics Inc. and ArchAngel Bioresearch! Full Circles Therapeutics is revolutionizing the field with its viral-free genome surgery platform, poised to make groundbreaking advancements in the treatment of severe genetic diseases and cancer. Their strong science was recognized by Novo Nordisk who awarded them as one of the winners for our Portal Pathbreakers program. Learn more about Full Circles here: https://fullcirclestx.com/ ArchAngel Bioresearch is pushing the boundaries of scientific discovery and bringing next level innovation through an AL/ML software for life sciences. We're excited to support your journey and witness your contributions to advancing bioresearch. Please join us in giving Hao Wu with Full Circles Therapeutics and Reginald Swift with Archangel Bioresearch a warm welcome to Southline! We look forward to the innovations and collaborations that will emerge from our shared space.

    • No alternative text description for this image
  • https://lnkd.in/gza4MSTV We're thrilled to announce that Full Circles Therapeutics has been awarded the prestigious #NovoNordisk #BioinnovationHub & #PortalInnovations, LLC Pathbreaker program! This recognition marks a significant milestone for us as we join Portal Innovations' biotech ecosystem. With this award, we're reaffirming our commitment to advancing platform innovation through our efficient, programmable, immune-quiescent and scalable #C4DNA gene writing platform. This platform, stemmed from a mini-circular single stranded DNA, is set to revolutionize non-viral cell and gene therapies for oncology, autoimmune, and genetically defined diseases, paving the way for the next generation of genomic medicine. Thank you to Novo Nordisk and Portal Innovations for this incredible opportunity. We look forward to continuing our journey of innovation and making a meaningful impact in healthcare. Stay tuned for more updates on our progress! #Biotechnology #Innovation #Healthcare #GeneTherapy #CellTherapy

    Portal Pathbreakers with Pharma - Portal Innovations

    Portal Pathbreakers with Pharma - Portal Innovations

    https://www.portalinnovations.com

  • We made it! We're thrilled to be part of the 2024 CDL #AdvancedTherapies cohort and to have graduated after many months of rigorous sessions. As we celebrate our accomplishments over the past few months, we want to extend our gratitude to the mentors and venture managers from CDL who generously donated their time to work with us. Joining the CDL ecosystem, we are now more confident as we look forward to advancing our #C4DNA based nonviral genomic medicine as a solution for next-generation cell and gene therapies.

    • No alternative text description for this image
  • Full Circles Therapeutics Inc. reposted this

    View profile for Hao Wu, graphic

    Co-Founder and CSO at Gene Editing Biotech, inventor for Epigenetic editing

    Today, on Rare Disease Day, Full Circles Therapeutics stands alongside the global community to shed light on the challenges faced by those affected by rare diseases. At Full Circles, we believe in the power of innovation and determination to pave the way for groundbreaking therapies. On this significant day, we proudly share our dedication and commitment to leveraging our non-viral gene writing approach in providing a path to cure for countless patients who await revolutionary therapies. By harnessing the potential of non-viral gene writing, we strive to unlock new possibilities for patients battling rare diseases. Our commitment extends beyond conventional boundaries as we work tirelessly to develop transformative therapies that offer hope and healing. #RareDiseaseDay #FullCircles #GeneTherapy #Cure #Geneediting

    • No alternative text description for this image

Similar pages

Funding